Harvard Bioscience, Inc. (HBIO)
| Previous close | 3.9200 |
| Open | 3.8400 |
| Bid | 2.9100 x 200 |
| Ask | 4.9600 x 200 |
| Day's range | 3.7729 - 4.0450 |
| 52-week range | 3.4400 - 6.2000 |
| Volume | |
| Avg. volume | 90,944 |
| Market cap | 169.413M |
| Beta (5Y monthly) | 1.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0800 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.88 |
GuruFocus.comHarvard Bioscience Inc (HBIO) Q1 2024 Earnings: Challenges Persist Amidst Strategic Adjustments
First Quarter Reveals Revenue Decline and Net Loss, Despite Strong Gross Margin
ZacksHarvard Bioscience (HBIO) Q1 Earnings Match Estimates
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0% and 4.92%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireHarvard Bioscience Announces First Quarter 2024 Financial Results
Strong gross margin performance and focus on efficiency to support ongoing investments in growthHOLLISTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. Jim Green, Chairman and CEO, said, “As expected, our first quarter revenues reflect ongoing market headwinds, especially in APAC, amplified by a strong prior year comparison. Despite these headwinds, we were pleased to
